Stay updated with breaking news from Third Harmonic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the
U.S. IND filed for THB335 with anticipated clinical trial start during 2Q’24 Strong financial position with cash and cash equivalents totaling $269.1 million as of December 31, 2023 SAN...
Celldex drug barzolvolimab has mid-stage results in a chronic inflammatory skin disease that top those of an approved Genentech drug and two experimental Novartis therapies. The biotech is preparing to advance its drug to Phase 3 testing in 2024.
Shares of Third Harmonic Bio, Inc. (THRD) climbs 17% on Tuesday after the company announced its next-generation product candidate, THB335, for the treatment of mast cell-mediated inflammatory diseases.
Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated Inflammatory DiseasesSAN FRANCISCO, May 11, 2023 -- Third Harmonic Bio, Inc. , a biopharmaceutical company... | May 11, 2023